| Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed BE Gryder, QH Sodji, AK Oyelere Future medicinal chemistry 4 (4), 505-524, 2012 | 446 | 2012 |
| CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity E Jacoby, SM Nguyen, TJ Fountaine, K Welp, B Gryder, H Qin, Y Yang, ... Nature communications 7 (1), 12320, 2016 | 412 | 2016 |
| PAX3–FOXO1 establishes myogenic super enhancers and confers BET bromodomain vulnerability BE Gryder, ME Yohe, HC Chou, X Zhang, J Marques, M Wachtel, ... Cancer Discovery 7 (8), 884-899, 2017 | 262 | 2017 |
| Long noncoding RNA PURPL suppresses basal p53 levels and promotes tumorigenicity in colorectal cancer XL Li, M Subramanian, MF Jones, R Chaudhary, DK Singh, X Zong, ... Cell reports 20 (10), 2408-2423, 2017 | 140 | 2017 |
| MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma ME Yohe, BE Gryder, JF Shern, YK Song, HC Chou, S Sindiri, A Mendoza, ... Science translational medicine 10 (448), eaan4470, 2018 | 128 | 2018 |
| Histone hyperacetylation disrupts core gene regulatory architecture in rhabdomyosarcoma BE Gryder, S Pomella, C Sayers, XS Wu, Y Song, AM Chiarella, S Bagchi, ... Nature genetics 51 (12), 1714-1722, 2019 | 127 | 2019 |
| Chemical genomics reveals histone deacetylases are required for core regulatory transcription BE Gryder, L Wu, GM Woldemichael, S Pomella, TR Quinn, PMC Park, ... Nature communications 10 (1), 3004, 2019 | 127 | 2019 |
| Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group V Patil, W Guerrant, PC Chen, B Gryder, DB Benicewicz, SI Khan, ... Bioorganic & medicinal chemistry 18 (1), 415-425, 2010 | 114 | 2010 |
| MultiDimensional ClinOmics for precision therapy of children and adolescent young adults with relapsed and refractory cancer: a report from the center for cancer research W Chang, AS Brohl, R Patidar, S Sindiri, JF Shern, JS Wei, YK Song, ... Clinical cancer research 22 (15), 3810-3820, 2016 | 107 | 2016 |
| Histone deacetylase inhibitors equipped with estrogen receptor modulation activity BE Gryder, MK Rood, KA Johnson, V Patil, ED Raftery, LPD Yao, M Rice, ... Journal of medicinal chemistry 56 (14), 5782-5796, 2013 | 99 | 2013 |
| Epigenetic siRNA and chemical screens identify SETD8 inhibition as a therapeutic strategy for p53 activation in high-risk neuroblastoma V Veschi, Z Liu, TC Voss, L Ozbun, B Gryder, C Yan, Y Hu, A Ma, J Jin, ... Cancer cell 31 (1), 50-63, 2017 | 94 | 2017 |
| Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells EC Dreaden, BE Gryder, LA Austin, BA Tene Defo, SC Hayden, M Pi, ... Bioconjugate chemistry 23 (8), 1507-1512, 2012 | 89 | 2012 |
| Prosurvival long noncoding RNA PINCR regulates a subset of p53 targets in human colorectal cancer cells by binding to Matrin 3 R Chaudhary, B Gryder, WS Woods, M Subramanian, MF Jones, XL Li, ... Elife 6, e23244, 2017 | 84 | 2017 |
| Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors BE Gryder, MJ Akbashev, MK Rood, ED Raftery, WM Meyers, P Dillard, ... ACS chemical biology 8 (11), 2550-2560, 2013 | 82 | 2013 |
| Insights into pediatric rhabdomyosarcoma research: Challenges and goals ME Yohe, CM Heske, E Stewart, PC Adamson, N Ahmed, CR Antonescu, ... Pediatric blood & cancer 66 (10), e27869, 2019 | 73 | 2019 |
| Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma IM Tenente, MN Hayes, MS Ignatius, K McCarthy, M Yohe, S Sindiri, ... Elife 6, e19214, 2017 | 69 | 2017 |
| Dose-dependent activation of gene expression is achieved using CRISPR and small molecules that recruit endogenous chromatin machinery AM Chiarella, KV Butler, BE Gryder, D Lu, TA Wang, X Yu, S Pomella, ... Nature biotechnology 38 (1), 50-55, 2020 | 66 | 2020 |
| Vangl2/RhoA signaling pathway regulates stem cell self-renewal programs and growth in rhabdomyosarcoma MN Hayes, K McCarthy, A Jin, ML Oliveira, S Iyer, SP Garcia, S Sindiri, ... Cell stem cell 22 (3), 414-427. e6, 2018 | 66 | 2018 |
| Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma D Bogen, JS Wei, DO Azorsa, P Ormanoglu, E Buehler, R Guha, JM Keller, ... Oncotarget 6 (34), 35247, 2015 | 58 | 2015 |
| Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma T McKinnon, R Venier, M Yohe, S Sindiri, BE Gryder, JF Shern, L Kabaroff, ... Oncogene 37 (20), 2630-2644, 2018 | 45 | 2018 |
Javed KhanDeputy Branch Chief Genetics Branch, Senior Investigator, Center for Cancer Research, NCI, NIH在 mail.nih.gov 的电子邮件经过验证
